Enfuvirtidacetat (T-20)
Alias:Fuzeon
Sekvens:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas No. : 159519-65-0
Molekylær formel : C204H301N51O64
Molekylær vekt : 4492
Renhet (HPLC) : 98.0%min.
Utseende : Hvitt til off-white amorft fast stoff
Enkel Urenhet (HPLC) : 0.5%maks
Aminosyresammensetning : ±10 % av teoretisk
Peptidinnhold (N %) : ≥80,0 %
Vanninnhold (Karl Fischer) : ≤8,0 %
Trifluoracetat-innhold(HPIC) : ≤12,0 %
MS (ESI) : Konsistent
Massebalanse : 95.0~105,0 %
Karakter : Farmasøytisk karakter
Oppbevaring: Lukket, under 2 ~ 8℃ bevaring
Bruk : Behandlingsalternativ for pasienter som lider av HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (VERTSHUS) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
